Prevention and treatment of respiratory syncytial virus bronchiolitis and postbronchiolitic wheezing by unknown
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BPD = bronchopulmonary dysplasia; IFN = interferon; LRTI = lower respiratory tract infection; RAD = reactive airway disease; RSV = respiratory
syncytial virus; RSV-IGIV = respiratory syncytial virus immune globulin intravenous (human).
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Introduction
Respiratory syncytial virus (RSV) can cause acute clinical
findings that range from symptoms of upper respiratory
infection, with or without otitis media, to severe lower res-
piratory tract disease. Virtually all children become
infected with RSV within 2 years of birth, most commonly
before 6 months of age, and 1% require hospitalization
[1]. RSV is the primary cause of hospitalization for acute
respiratory tract illness in young children, and it may be
responsible for 40–90% of cases of bronchiolitis, for
5–40% of cases of pneumonia, and for 10–30% of cases
of tracheobronchitis in this age group [2].
RSV is transmitted most commonly by direct contact with
surfaces or persons contaminated with infectious nasal
secretions. After an incubation period of 2–8 days, RSV
replicates in the nasopharyngeal epithelium and can
spread to the lower respiratory tract within 1–3 days [3].
Pneumonia or bronchiolitis occurs in 30–71% of infants
and young children at the time of first RSV infection [4].
RSV bronchiolitis is often followed by recurrent episodes
of wheezing, although the pathogenesis of this link is
poorly understood. Bont et al. [5] found that 47% of 130
infants hospitalized for RSV lower respiratory tract infec-
tion (LRTI) developed recurrent wheezing during a 1-year
follow up. The occurrence of wheezing was significantly
higher in infants with airflow limitation (61%) than for
those without airflow limitation (21%; P < 0.001) during
the acute infection. In a study by conducted by Stein et al.
[6], 207 children who had RSV LRTI before age 3 years
also had a significantly increased risk for both infrequent
wheezing and frequent wheezing by age 6 years (3.2 and
4.3 times greater incidence than in children who did not
have RSV LRTI before age 3 years, respectively;
P < 0.001). However, this risk decreased and was no
longer significant by age 13 years, and none of the
patients was hospitalized. Sigurs et al. [7] demonstrated
that RSV bronchiolitis that was severe enough to require
hospitalization in 47 infants was highly associated
(P < 0.001) with development of asthma and recurrent
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wheeze up to age 7.5 years. The cumulative prevalence of
asthma was 30% in the RSV group and 3% in the control
group (P < 0.001), and the cumulative prevalence rates of
any wheezing were 68% and 34%, respectively (P < 0.001).
The majority of children who experience postbronchiolitic
wheezing have multiple (recurrent) episodes. Hall [3] cited
subsequent episodes of wheezing in 40–50% of infants
hospitalized with RSV bronchiolitis, imposing a significant
burden on health care resources. During the 1980s, an
estimated 100,000 children were hospitalized with RSV
infection in the USA annually [3,8], at a cost of US$300
million. In the study conducted by Bont et al. [5] recurrent
wheezing in the hospitalized infants was defined as two or
more episodes; respiratory symptoms were recorded in a
daily diary. Infants had a total of 241 episodes of wheez-
ing, with a median number of two episodes.
It is difficult to predict which children will develop recurrent
wheezing, although some clinical and immunologic para-
meters may be useful in prediction models in the future.
Airflow limitation during RSV LRTI is the first useful clinical
predictor of subsequent recurrent wheezing and physician
diagnosed asthma in early childhood [5]. Another predictor
may be monocyte interleukin-10 responses in vitro to stim-
ulation with nonspecific stimuli [9]. In addition, a high
(≥16 µg/l) serum eosinophil cationic protein concentration
during the acute phase of bronchiolitis is a specific but
insensitive predictor of wheezing after bronchiolitis [10].
Thus, a high serum level of eosinophil cationic protein is
strongly predictive of subsequent wheezing, but low values
do not exclude wheezing episodes in the future.
The pathogenesis of recurrent wheezing after RSV LRTI is
not completely understood. Prospective, randomized
studies are needed to determine whether severe RSV LRTI
causes long-term pulmonary sequelae and a predisposition
to wheezing, or whether inherent genetic or structural
abnormalities predispose a child to both severe LRTI and
wheezing later in life. If severe RSV LRTI causes subse-
quent wheezing, then reducing the severity of RSV LRTI
should reduce the risk for subsequent wheezing. This issue
has been explored in several studies of RSV LRTI treat-
ment or prevention; these studies are discussed below.
Therapy for respiratory syncytial virus
bronchiolitis
Antiviral therapy with aerosolized ribavirin and sympto-
matic therapy with bronchodilators and corticosteroids are
the available treatment options for RSV infections. Unfor-
tunately, they produce only a modest short-term improve-
ment in respiratory outcome, or have no effect at all.
Ribavirin is a synthetic guanosine analog and broad-
spectrum antiviral agent that is approved only for hospital-
ized infants and young children with severe RSV infection.
Ribavirin inhibits RSV replication during the active replica-
tion phase. Use of aerosolized ribavirin has been associ-
ated with improved oxygenation and clinical scores [11]
and with reduced levels of secretory mediators of inflam-
mation associated with severe disease and wheezing [12].
However, some investigations were criticized for their
methodology and use of subjective end-points (e.g. clini-
cal score) rather than objective end-points (e.g. mortality,
arterial oxygen saturation, and need for or duration of
mechanical ventilation) [13]. Any beneficial effects of rib-
avirin, such as a reduction in duration of mechanical venti-
lation or hospitalization, are unproven [3], and routine use
in high-risk children with RSV infections is no longer war-
ranted [13].
Most available data do not support the use of cortico-
steroids in the treatment of acute RSV bronchiolitis. Intra-
venous hydrocortisone followed by oral prednisone [14],
intramuscular or oral dexamethasone [15,16], and oral
prednisolone [17] have yielded little or no benefit, except
possibly in a select subgroup of patients.
Several trials [18–21] have also shown that β2-agonist
bronchodilators, such as salbutamol and the anticholinergic
agent ipratropium bromide, have no beneficial effect on
acute RSV bronchiolitis. Although bronchodilators may
produce a modest short-term improvement in clinical scores
[13], Flores and Horwitz [22] concluded (on the basis of an
extensive meta-analysis) that there is insufficient evidence to
support the use of β2-agonists to treat bronchiolitis.
Studies of the efficacy of vitamin A [23] and interferon [24]
also had disappointing results. Oral administration of vitamin
A did not decrease respiratory morbidity in children with
acute RSV bronchiolitis [23]. In a double-blind, placebo-
controlled study [24], IFN-α-2a had a prophylactic effect
but did not reduce the severity of signs and symptoms or
duration of illness. There was a significant difference
(P < 0.05) in the frequency of colds in the two groups: one
out of 19 receiving IFN-α-2a and seven out of 19 receiving
placebo had colds. Also, 14 out of 19 receiving placebo
showed laboratory evidence of RSV infection, versus 10 of
19 receiving IFN-α-2a. Because the risk for a secondary
bacterial infection in patients with RSV bronchiolitis is very
low [25], routine use of antibiotics is not warranted.
The results of two therapeutic trials with RSV intravenous
immune globulin (RSV-IGIV; RespiGamTM, MedImmune,
Inc., Gaithersburg, MD, USA) were also disappointing.
RSV-IGIV was no more effective than placebo in previ-
ously healthy children hospitalized with RSV infection with
regard to duration of stay either in hospital or on the inten-
sive care unit [26], or was it beneficial in hospitalized chil-
dren at high risk for severe RSV infection [27]. However,
RSV-IGIV has been shown to be effective in the preven-
tion of RSV LRTI in these high-risk children.
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Prophylaxis for respiratory syncytial virus
bronchiolitis
Prevention of RSV bronchiolitis has met with greater
success than has treatment. Although no vaccine is avail-
able to prevent RSV bronchiolitis, passive immunization can
be conferred by RSV-IGIV, which contains high levels of
RSV neutralizing antibody, or by intramuscular injections of
the humanized monoclonal antibody palivizumab (Synagis®;
MedImmune, Inc.). Both products are costly, however.
Vaccines
The development of vaccines for RSV has been con-
founded by failure to achieve durable immunity, even after
natural infection, and by an incomplete understanding of
the immune response to RSV. In the 1960s, a formalin-
inactivated aluminum-precipitated vaccine failed to protect
infants and children against naturally acquired RSV infec-
tion. Furthermore, on rechallenge with RSV the vaccine
induced an immune-mediated response, resulting in
increased hospitalizations for lower respiratory tract
pathology and increased mortality [28–30].
Even if an effective vaccine could be developed that pro-
tects for at least the first few years of life, it might not be
available for general use for another 5–10 years. Vaccina-
tion research has produced such candidates as the
recombinant vaccine BBG2Na; subunit vaccines such as
the purified fusion protein-2; and cold-passaged, tempera-
ture-sensitive vaccines. However, phase III efficacy trials in
infants, young children, and the elderly are still lacking. In a
phase I trial, the recombinant fusion protein BBG2Na was
highly immunogenic and well tolerated, and had few side
effects in healthy volunteers [13]. The use of purified
fusion protein-2, which contains fusion protein of approxi-
mately 98% purity and small quantities of other virus pro-
teins [31], resulted in a good immune response and a
significant reduction in LRTIs in RSV-seropositive children
with cystic fibrosis during the RSV season [32]. Important
side effects, including upper respiratory tract symptoms
such as nasal congestion, were observed with several
candidate attenuated vaccines, particularly in infants
younger than 2 months [13].
Respiratory syncytial virus immune globulin intravenous
Passive immunization with RSV-IGIV is effective as long as
the neutralizing antibody titer is adequate. For example, in
a study conducted by Groothuis et al. [33], 249 high-risk
infants and young children with or without chronic lung
disease and those with congenital heart disease were ran-
domized to receive monthly infusions of high-dose RSV-
IGIV (750 mg/kg body weight, n = 81), low-dose
RSV-IGIV (150 mg/kg body weight, n = 79), or no prophy-
laxis (n = 89). The high-dose group showed a significant
reduction (62%; P = 0.01) in the incidence of all RSV
LRTIs and a 72% reduction (P = 0.03) in moderate or
severe RSV LRTIs. Furthermore, the high-dose group had
significantly fewer hospitalizations and hospital days
(63%; P = 0.02), fewer days in the intensive care unit
(97–100% reduction for both high and low doses;
P = 0.05 for high dose and P = 0.03 for low dose), and
decreased use of ribavirin (9%; P = 0.05). The greatest
benefit of RSV-IGIV was observed in preterm infants with
or without bronchopulmonary dysplasia (BPD). In a sub-
analysis of that study [34], high-dose RSV-IGIV signifi-
cantly reduced (P = 0.006) the incidence of moderate to
severe RSV LRTIs and also decreased RSV hospitaliza-
tions in preterm infants with or without BPD (n = 58)
versus placebo (n = 58; P = 0.06).
The PREVENT trial [35] found that monthly high-dose RSV-
IGIV (750 mg/kg, n = 250) in infants with prematurity and
BPD was associated with a 41% reduction in hospitaliza-
tions and 53% fewer days of hospitalization for RSV as
compared with the placebo group (n = 260). The number of
patients requiring mechanical ventilation, however, did not
differ between the two groups. There was also no difference
in the proportion of children who reported adverse events.
Drawbacks associated with the use of RSV-IGIV are the
long duration of intravenous administration (several hours),
the considerable volume needed (15 ml/kg), possible
interference with normal vaccinations, and high cost. RSV-
IGIV is not recommended in infants with cyanotic congeni-
tal heart disease because it was associated with a high
rate of adverse events.
Palivizumab
Palivizumab is an IgG1 humanized monoclonal antibody
that exhibits neutralizing and fusion-inhibitory activity
against RSV. In the randomized, double-blind, multicenter
IMpact-RSV Trial [36], monthly palivizumab prophylaxis by
intramuscular injection (15 mg/kg body weight, n = 1002)
versus placebo (n = 500) resulted in a significant reduc-
tion (55%; P = 0.00004) in RSV-related hospitalization in
high-risk premature infants or infants with BPD. During the
150-day follow up, premature infants without BPD bene-
fited most from the therapy. Palivizumab was safe and well
tolerated, and there were no serious side effects or signifi-
cant differences between the placebo and treatment
groups in adverse events.
The advantages of palivizumab are its easy administration
and lack of interference with normal vaccinations. As a
result, it is generally used more commonly than RSV-IGIV.
Its major disadvantage is its high cost. Other IgG mono-
clonal antibodies are being studied that may be future
candidates for phase III clinical trials of prevention of RSV
infection in high-risk infants.
Prevention of recurrent wheezing episodes
If the recurrent wheezing episodes associated with severe
RSV LRTIs in infants are in fact due to the initial RSV
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infection, then these sequelae might be prevented in one
of two ways. One is treating the initial RSV bronchiolitis
episode in order to lessen its severity; treatment options
include ribavirin and corticosteroids. The other option is to
prevent RSV bronchiolitis; effective options include RSV-
IGIV and palivizumab [37].
Ribavirin
Several studies have shown that ribavirin therapy for RSV
LRTI appears to have no significant effect on long-term
respiratory outcomes, although it may affect short-term
outcomes. In the first study of ribavirin and its long-term
sequelae in children hospitalized with RSV LRTI, Krilov et
al. [38] identified no difference in the incidence of reactive
airway disease (RAD) or in pulmonary function 6 years
after treatment in those who received ribavirin (n = 33)
and age-matched control children (n = 67). In that study,
the ribavirin group had more severe disease. Similarly, a 9-
year follow-up study of children hospitalized for RSV LRTI
conducted by Long et al. [39] suggested that those ran-
domized to receive ribavirin (n = 28) did not have a better
outcome than did those randomized to receive placebo
(n = 26). There were no differences between the two
groups for any of the parameters studied, including recur-
rent LRTI, wheezing, and pulmonary function.
In a 7-year follow-up study, Rodriguez et al. [40] found no
difference in RAD, wheezing, or pneumonia between chil-
dren who received ribavirin (n = 24) and those who
received placebo (n = 11), and no difference in results of
methacholine challenge tests. However, none of six
placebo patients had normal or mildly abnormal pulmonary
function test results as compared with seven out of 13 rib-
avirin-treated patients. In contrast, the results of a 1-year
retrospective study [41] suggest that ribavirin therapy
might affect the short-term outcome of severe RSV bron-
chiolitis. Infants who received ribavirin (n = 22) had a sig-
nificant reduction (P < 0.05) in the prevalence of RAD as
compared with those who underwent conservative man-
agement (n = 19), both in terms of percentage of patients
developing airway reactivity (59% and 89%, respectively)
and number of episodes of RAD (31 and 70, respectively).
Available online http://respiratory-research.com/content/3/S1/S40
Table 1
Effect of corticosteroids on recurrent wheezing
Children Proven 
treated/ RSV Corticosteroid Duration 
control infection or other of 
Reference Effect children (n) (n) drug therapy follow-up Comments
[43] Positive 68/120 All Salbutamol, epinephrine, 24 months Group 2 (86% received corticosteroids after discharge) 
betamethasone, had less asthma and fewer severe respiratory symptoms 
terbutaline, budesonide versus group 1 (13% with persistent symptoms received 
drug after discharge)
[44] Positive 40/41 All Budesonide for 1 week 2 years Fewer patients in 1-week group (18%) and 8-week group 
or 8 weeks (12%) had asthma versus control group (37%; P < 0.02)
[45] Positive Cromolyn 34; 21 Budesonide; cromolyn 16 weeks Fewer wheezing episodes in last 8 weeks (cromolyn 19%, 
budesonide 34; sodium budesonide 16%, controls 47%; P < 0.05)
controls 32
[46] Positive 20/21 Not Beclomethasone 12 weeks Wheezing (P = 0.005) and sleep patterns (P < 0.005) 
identified dipropionate significantly improved in treated group at 6 weeks
[47] None 83/82 All Budesonide 12 months No differences in duration of hospital admission, time to 
become symptom free, readmission rates, general 
practitioner consultation rates, or use of antiwheeze 
medication during follow up
[48] None Cromolyn 29; 23 Budesonide; cromolyn 3 years Therapy for 4 months did not affect occurrence of asthma 
budesonide 31; sodium at 3 years
controls 29
[49] None 27/27 All Prednisolone 3–7 years No difference in number of wheezers by age 5 years
[50] None 26/28 35 Budesonide 12 months No difference in hospital admissions or increase in 
symptoms at 1 year
[51] None 20/18 50% in Prednisone 2 years Similar prevalence of chronic respiratory symptoms at 
each group 2 years
[52] None 21/19 83% Budesonide 6 months No difference in prevalence of wheeze, cough/wheeze 
scores, or bronchodilator use
RSV, respiratory syncytial virus.
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Corticosteroids
Corticosteroids to reduce local inflammation and bron-
chodilators to relax airway smooth muscle at the time of
acute RSV infection were considered for several reasons
[42]. First, there is a striking similarity between the clinical
syndromes of bronchiolitis and childhood asthma, for
which bronchodilators and corticosteroids are the main-
stays of treatment. Second, RSV bronchiolitis is often fol-
lowed by recurrent episodes of wheezing. Finally,
bronchiolitis and childhood asthma have pathophysiologic
and immunopathogenic mechanisms in common. The
available data fail to show that corticosteroid therapy
during or after RSV bronchiolitis effectively prevents recur-
rent wheezing. Only four out of the 10 studies [43–52]
shown in Table 1 demonstrated any positive effect. In
addition, the prevalence of postbronchiolitic wheezing was
not reduced by oral prednisone with nebulized budes-
onide during the acute infection [52]. Although there are
some indications that corticosteroids may have an effect in
patients with more severe infection [53], longer-term
studies, especially those that include pulmonary function
testing, are needed.
Respiratory syncytial virus immune globulin intravenous
In a study conducted at the University of Colorado School
of Medicine and Children’s Hospital, Wenzel et al. [54]
investigated the use of RSV-IGIV to prevent recurrent
wheezing. Those investigators found that RSV-IGIV pro-
phylaxis may have long-term effects on clinical and
immunologic parameters of recurrent wheezing.
Palivizumab
Currently, no data are available on the use of palivizumab
for treatment or prevention of bronchiolitis, or prevention
of recurrent wheezing, although one study is underway
(Protocol W00-353; Abbott Laboratories, Abbott Park, IL,
USA). Children who have received palivizumab will be
compared with children who have had documented RSV
bronchiolitis and control children. Approximately 100 chil-
dren will be enrolled in each cohort. They will be followed
for 3 years by means of monthly telephone calls and office
visits at 6, 12, 24, and 36 months. Outcomes will consist
of a respiratory questionnaire, incidence of wheezing,
medications used, hospitalizations, and pharmaco-
economic evaluation. Results are expected in late 2003.
Conclusion
Studies have shown that ribavirin therapy appears to have
no significant effect on reducing the long-term respiratory
outcomes associated with RSV LRTI. Inhaled cortico-
steroid or bronchodilator therapy administered at the time
of acute RSV infection may improve respiratory outcomes
only in the short term. RSV-IGIV and palivizumab are effec-
tive agents for prevention of RSV LRTI in children with
BPD and/or prematurity, but their long-term effect on the
development of asthma and recurrent wheezing is not
clear. Further research is needed to elucidate the mecha-
nisms involved and to evaluate the impact of available ther-
apies on long-term respiratory outcomes of RSV LRTI.
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